6562 Federal Register / Vol. 87, No. 24 / Friday, February 4, 2022 / Notices 

(clinical and laboratory testing); 

promote TB, MDR–TB, and TB/HIV 

prevention and integration into existing 

healthcare services; strengthen TB 

surveillance and monitoring and 

evaluation (M&E) and improve 

collaboration and coordination between 

TB and other programs, particularly HIV 

and COVID–19. Funding amounts for 

years 2–5 will be set at continuation. 

DATES: The period for this award will be 

September 30, 2022 through September 

29, 2027. 

FOR FURTHER INFORMATION CONTACT: 

Amy Bailey, Center for Global Health, 

Centers for Disease Control and 

Prevention, 5th/Floor Tung Shing 

Building, No 2, Ngo Quyen Street, Hoan 

Kiem District Hanoi, Vietnam, 

Telephone: 800–232–6348, email: fue8@

cdc.gov. 

SUPPLEMENTARY INFORMATION: The 

single-source award will contribute to 

enhancing early and universal access to 

high quality prevention, diagnosis, and 

treatment services for TB, MDR–TB, and 

TB/HIV with the goal of ending TB in 

Vietnam by 2030. 

The NLH/NTP is in a unique position 

to conduct this work as it is mandated 

by Vietnam Ministry of Health (MoH) 

with oversight and implementation of 

TB prevention and control activities in 

Vietnam. The NLH is the leading 

tertiary hospital in charge of 

examination and treatment of TB and 

lung diseases and steering TB and lung 

disease prevention and control activities 

throughout the country. 

Summary of the Award 

Recipient: National Lung Hospital 

(NLH)/National Tuberculosis Program 

(NTP). 

Purpose of the Award: The purpose of 

this award is to support high quality TB, 

MDR–TB, and TB/HIV programs to 

strengthen and expand TB and MDR–TB 

quality-assured diagnostic capacity 

(clinical and laboratory testing); 

promote TB, MDR–TB, and TB/HIV 

prevention and integration into existing 

healthcare services; strengthen TB 

surveillance and M&E and improve 

collaboration and coordination between 

TB and other programs, particularly HIV 

and COVID–19. 

Amount of Award: The approximate 

year 1 funding amount will be 

$1,500,000 in Federal Fiscal Year (FYY) 

2022 funds, subject to the availability of 

funds. Funding amounts for years 2–5 

will be set at continuation. 

Authority: This program is authorized 

under Public Law 108–25 (the United 

States Leadership Against HIV AIDS, 

Tuberculosis and Malaria Act of 2003). 

Period of Performance: September 30, 

2022 through September 29, 2027. 

Dated: February 1, 2022. 

Terrance Perry, 

Chief Grants Management Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2022–02412 Filed 2–3–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP); 

SIP22–001, Process, Outcome, and Cost 

Evaluation of Free Sunscreen 

Dispensers in Outdoor Community 

Settings. 

Date: April 26, 2022. 

Time: 11:00 a.m.–6:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Jaya 

Raman Ph.D., Scientific Review Officer, 

National Center for Chronic Disease 

Prevention and Health Promotion, CDC, 

4770 Buford Highway, Mailstop S107– 

B, Atlanta, Georgia 30341, Telephone: 

(770) 488–6511, Email: JRaman@

cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–02381 Filed 2–3–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP): 

RFA–PS–22–001, Implementing Preexposure Prophylaxis for HIV 

Prevention in Syringe Service Programs; 

RFA–PS–22–002, Implementation 

Research on Telehealth Strategies to 

Support Retention in Care and 

Treatment among Antiretroviral 

Therapy (ART) Patients and Preexposure Prophylaxis (PrEP) Clients; 

and RFA–PS–22–004, Understanding 

HIV/STD Risk and Enhancing PrEP 

Implementation Messaging in a Diverse 

Community-Based Sample of Gay, 

Bisexual, and Other Men Who Have Sex 

with Men in a Transformational Era. 

Date: March 30, 2022. 

Time: 10:00 a.m.–5:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Gregory Anderson, M.S., M.P.H., 

Scientific Review Officer, CDC, National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention, 1600 Clifton Road, 

NE, Mailstop US8–1, Atlanta, Georgia 


lotter on DSK11XQN23PROD with NOTICES1